Goldenwell Biotech (GWLL) Cash & Equivalents (2019 - 2025)
Goldenwell Biotech (GWLL) has disclosed Cash & Equivalents for 7 consecutive years, with $45622.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Cash & Equivalents rose 859.45% year-over-year to $45622.0, compared with a TTM value of $45622.0 through Sep 2025, up 859.45%, and an annual FY2024 reading of $49404.0, down 7.19% over the prior year.
- Cash & Equivalents was $45622.0 for Q3 2025 at Goldenwell Biotech, down from $76507.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $248569.0 in Q1 2021 and bottomed at $4755.0 in Q3 2024.
- Average Cash & Equivalents over 5 years is $87931.7, with a median of $45996.0 recorded in 2022.
- The sharpest move saw Cash & Equivalents tumbled 82.54% in 2022, then surged 859.45% in 2025.
- Year by year, Cash & Equivalents stood at $213556.0 in 2021, then plummeted by 78.46% to $45996.0 in 2022, then rose by 15.73% to $53231.0 in 2023, then dropped by 7.19% to $49404.0 in 2024, then fell by 7.66% to $45622.0 in 2025.
- Business Quant data shows Cash & Equivalents for GWLL at $45622.0 in Q3 2025, $76507.0 in Q2 2025, and $17127.0 in Q1 2025.